Evidence map›Paper›PMID 17367540›Full record

ArticleBMC pediatrics2007

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Anand Reddi, Sarah C Leeper, Anneke C Grobler, Rosemary Geddes, K Holly France, Gillian L Dorse, Willem J Vlok, Mbali Mntambo, Monty Thomas, Kristy Nixon and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC pediatrics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04194021 (Demographic, Clinical, and Laboratory Characteristics and Outcomes of Patients Who Ever Received Etravirine and/or Darunavir - Multi-country Data Abstraction), which is not on this map. Cited by 84 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 4 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04194021 unknown statusnot on this mapstarted 2019, after this paper: background citation

Demographic, Clinical, and Laboratory Characteristics and Outcomes of Patients Who Ever Received Etravirine and/or Darunavir - Multi-country Data Abstraction

TypeobservationalSponsorElizabeth Glaser Pediatric AIDS FoundationRan2019 to 2023Enrolled871ConditionsHIV/AIDS
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 4 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Anand ReddiSinikithemba HIV/AIDS Clinic, McCord Hospital, Durban, South Africa. areddi@fulbrightweb.org
Sarah C Leeper
Anneke C Grobler
Rosemary Geddes
K Holly France
Gillian L Dorse
Willem J Vlok
Mbali Mntambo
Monty Thomas
Kristy Nixon
Helga L Holst
Quarraisha Abdool Karim
Nigel C Rollins
Hoosen M Coovadia
Janet Giddy
McCord Hospital · ZAUniversity of KwaZulu-Natal · ZACentre for the AIDS Programme of Research in South Africa · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies address the use of paediatric highly active antiretroviral therapy (HAART) in Africa.

methodsWe performed a retrospective cohort study to investigate preliminary outcomes of all children eligible for HAART at Sinikithemba HIV/AIDS clinic in KwaZulu-Natal, South Africa. Immunologic, virologic, clinical, mortality, primary caregiver, and psychosocial variables were collected and analyzed.

resultsFrom August 31, 2003 until October 31, 2005, 151 children initiated HAART. The median age at HAART initiation was 5.7 years (range 0.3-15.4). Median follow-up time of the cohort after HAART initiation was 8 months (IQR 3.5-13.5). The median change in CD4% from baseline (p < 0.001) was 10.2 (IQR 5.0-13.8) at 6 months (n = 90), and 16.2 (IQR 9.6-20.3) at 12 months (n = 59). Viral loads (VLs) were available for 100 children at 6 months of which 84% had HIV-1 RNA levels < or = 50 copies/mL. At 12 months, 80.3% (n = 61) had undetectable VLs. Sixty-five out of 88 children (73.8%) reported a significant increase (p < 0.001) in weight after the first month. Eighty-nine percent of the cohort (n = 132) reported < or = 2 missed doses during any given treatment month (> 95%adherence). Seventeen patients (11.3%) had a regimen change; two (1.3%) were due to antiretroviral toxicity. The Kaplan-Meier one year survival estimate was 90.9% (95%confidence interval (CI) 84.8-94.6). Thirteen children died during follow-up (8.6%), one changed service provider, and no children were lost to follow-up. All 13 deaths occurred in children with advanced HIV disease within 5 months of treatment initiation. In multivariate analysis of baseline variables against mortality using Cox proportional-hazards model, chronic gastroenteritis was associated with death [hazard ratio (HR), 12.34; 95% CI, 1.27-119.71) and an HIV-positive primary caregiver was found to be protective against mortality [HR, 0.12; 95% CI, 0.02-0.88). Age, orphanhood, baseline CD4%, and hemoglobin were not predicators of mortality in our cohort. Fifty-two percent of the cohort had at least one HIV-positive primary caregiver, and 38.4% had at least one primary caregiver also on HAART at Sinikithemba clinic.

conclusionThis report suggests that paediatric HAART can be effective despite the challenges of a resource-limited setting.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentCaregiversCD4 Lymphocyte CountChildChild, PreschoolChronic DiseaseCohort StudiesFemaleGastroenteritisHIV InfectionsHumansMalePatient ComplianceProportional Hazards ModelsRetrospective Studies

Identifiers

PMID17367540
PMCPMC1847430
OpenAlexW2085628809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.